EX-99.1 2 tv521087_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1 




Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights


Safety study completed; Expect to report data from 2nd pivotal Phase 3 trial by the end of second quarter 2019


New York, NY – May 13, 2019 – Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2019.


“We recently completed the safety study for IV tramadol and expect to report data by the end of this quarter from our pivotal Phase 3 trial of IV tramadol for the management of postoperative pain in patients following abdominoplasty surgery,” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer. “We look forward to the results from this important study, as it not only compares IV tramadol to placebo, but also includes an active-comparator arm of IV morphine.”


Recent Achievements:


·The Company has completed the open-label, single-arm safety study of IV tramadol in post-surgical pain. The results show that IV tramadol is well-tolerated with a side effect profile consistent with known pharmacology.
·In April 2019, Avenue announced the appointment of Dr. Thomas G. Moore to its Board of Directors.


Financial Results:


·Cash Position: As of March 31, 2019, Avenue’s cash and cash equivalents totaled $29.4 million, compared to $2.7 million at December 31, 2018. The $26.7 million increase was primarily attributable to the stock purchase by InvaGen Pharmaceuticals Inc. (“InvaGen”) in connection with the first stage closing of the agreement between InvaGen and Avenue.
·R&D Expenses: Research and development expenses for the three months ended March 31, 2019, were $10.2 million, compared to $9.4 million for the same quarter in 2018. The $0.8 million increase was primarily attributable to the ongoing Phase 3 trial of IV tramadol following abdominoplasty surgery and to the Phase 3 safety trial of IV tramadol.
·G&A Expenses: General and administrative expenses for the three months ended March 31, 2019, were $1.1 million, compared to $1.0 million for the same quarter in 2018. The $0.1 million increase was primarily attributable to an increase in non-cash stock compensation offset by reductions in market research costs and professional fees.
·Net Loss: Net loss attributable to common stockholders for the three months ended March 31, 2019, was $11.3 million, or $0.82 per share, compared to a net loss of $10.4 million, or $1.03 per share, for the three months ended March 31, 2018.





About Avenue Therapeutics

Avenue is a specialty pharmaceutical company focused on the development and commercialization of IV Tramadol for the management of moderate to moderately severe post-operative pain. IV Tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics. Avenue is currently evaluating IV Tramadol in a pivotal Phase 3 program for the management of post-operative pain. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.avenuetx.com.


Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.



Jaclyn Jaffe and William Begien

Avenue Therapeutics, Inc.

(781) 652-4500







Condensed Balance Sheets
($ in thousands, except for share and per share amounts)


   March 31,   December 31, 
   2019   2018 
Current Assets:          
Cash and cash equivalents  $29,448   $2,671 
Deferred financing costs   61    1,702 
Prepaid expenses and other current assets   254    152 
Total Assets  $29,763   $4,525 
Current Liabilities:          
Accounts payable and accrued expenses  $9,326   $4,669 
Accounts payable and accrued expenses - related party   86    487 
Total current liabilities   9,412    5,156 
Total Liabilities   9,412    5,156 
Commitments and Contingencies          
Stockholders' Equity (Deficit)          
Preferred Stock ($0.0001 par value), 2,000,000 shares authorized          
Class A Preferred Stock, 250,000 shares issued and outstanding as of March 31, 2019 and December 31, 2018   -    - 
Common Stock ($0.0001 par value), 50,000,000 shares authorized          
Common shares; 16,557,122 and 10,667,714 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively   2    1 
Additional paid-in capital   73,827    41,577 
Accumulated deficit   (53,478)   (42,209)
Total Stockholders' Equity (Deficit)   20,351    (631)
Total Liabilities and Stockholders' Equity (Deficit)  $29,763   $4,525 






Condensed Statements of Operations

($ in thousands, except for share and per share amounts)


   For the Three Months Ended 
   March 31,   March 31, 
   2019   2018 
Operating expenses:        
Research and development  $10,241   $9,439 
General and administrative   1,119    986 
Loss from operations   (11,360)   (10,425)
Interest income   (91)   (48)
Net Loss  $(11,269)  $(10,377)
Net loss per common share outstanding, basic and diluted  $(0.82)  $(1.03)
Weighted average number of common shares outstanding, basic and diluted   13,742,649    10,099,331